{"createdAt":"8/2/2020, 2:09:39 PM","timestamp":1596391779308,"Company ID number":"365","DMX_ISSUER_NAME":"China Meheco Group Co., Ltd.","DMX_ISSUER_ID":"IID000000002160628","Country of Classification":"CHINA","name":"China Meheco Group Co Ltd ","code":"600056","stock_exchange":"Shanghai Stock Exchange","people":[{"id":"中国医药健康产业股份有限公司_高渝文","group":"board","name":"高渝文","title":"董事长,董事","isMale":true,"age":"53","degree":"硕士","salary":"96.78万","stockAmount":"-","description":"高渝文先生,53岁,硕士,高级经济师。曾任中国通用技术(集团)控股有限责任公司医药事业本部副总经理、总经理、党委副书记;公司党委副书记、董事、总经理。现任中国医药健康产业股份有限公司党委书记、董事长。","lastUpdated":"2020-02-13"},{"id":"中国医药健康产业股份有限公司_王宏新","group":"board","name":"王宏新","title":"董事","isMale":true,"age":"53","degree":"硕士","salary":"82.96万","stockAmount":"-","description":"王宏新先生,53岁,硕士,助理国际商务师。中国医药健康产业股份有限公司综合贸易部总经理、公司总经理助理、董事、副总经理。现任中国医药健康产业股份有限公司总经理。","lastUpdated":"2020-06-18"},{"id":"中国医药健康产业股份有限公司_张天宇","group":"board","name":"张天宇","title":"职工董事","isMale":true,"age":"44","degree":"本科","salary":"57.79万","stockAmount":"-","description":"张天宇先生,44岁,大学本科。中国医药健康产业股份有限公司政治工作部副主任、党群工作部主任、工会副主席、公司职工监事。现任中国医药健康产业股份有限公司人力资源部总经理兼任总裁办公室主任、职工董事。","lastUpdated":"2020-01-23"},{"id":"中国医药健康产业股份有限公司_金鸿雁","group":"board","name":"金鸿雁","title":"董事","isMale":true,"age":"48","degree":"硕士","salary":"--","stockAmount":"-","description":"金鸿雁先生,48岁,硕士,高级会计师。曾任中国通用技术(集团)控股有限责任公司财务管理总部副总经理、副总经理(主持工作)。现任中国通用技术(集团)控股有限责任公司财务管理总部总经理、通用技术集团财务有限责任公司董事长。","lastUpdated":"2020-02-13"},{"id":"中国医药健康产业股份有限公司_陈华亮","group":"board","name":"陈华亮","title":"董事","isMale":true,"age":"58","degree":"硕士","salary":"--","stockAmount":"-","description":"陈华亮先生,58岁,硕士。曾任中国通用技术(集团)控股有限责任公司派驻二级公司专职监事、集团直属党委委员。现任中国通用技术(集团)控股有限责任公司派驻二级公司专职董事、集团直属党委委员。","lastUpdated":"2020-02-13"},{"id":"中国医药健康产业股份有限公司_徐一","group":"board","name":"徐一","title":"董事","isMale":true,"age":"44","degree":"本科","salary":"--","stockAmount":"-","description":"徐一先生,44岁,大学本科,助理工程师。曾任中国通用技术(集团)控股有限责任公司战略和发展总部总经理助理兼投资管理部经理。现任中国通用技术(集团)控股有限责任公司医药医疗健康事业部副总经理。","lastUpdated":"2020-02-13"},{"id":"中国医药健康产业股份有限公司_郭云沛","group":"board","name":"郭云沛","title":"独立董事","isMale":true,"age":"73","degree":"大专","salary":"--","stockAmount":"-","description":"郭云沛,1947年7月出生,中国国籍,无境外永久居留权,大专学历,高级编辑。曾担任中国医药报社副总编辑以及报社第一负责人、北京卓信医学传媒集团执行总裁、中国医药企业管理协会副会长、会长。2008年至今,任中国医药企业管理协会名誉会长、专家委员会执行主任。2015年11月至今,任北京玉德未来控股有限公司董事。2016年6月至今,兼任公司董事。","lastUpdated":"2020-02-13"},{"id":"中国医药健康产业股份有限公司_祝继高","group":"board","name":"祝继高","title":"独立董事","isMale":true,"age":"37","degree":"博士","salary":"10.00万","stockAmount":"-","description":"祝继高先生,37岁,教授,会计学博士。历任对外经济贸易大学国际商学院会计学讲师、副教授、教授、博士生导师。现任对外经济贸易大学国际商学院会计学教授、博士生导师;同时,任北京莱伯泰科仪器股份有限公司(未上市)、青木数字技术股份有限公司(未上市)、北京木瓜移动科技股份有限公司(未上市)及方正富邦基金管理有限公司独立董事。2016年8月至今,任公司独立董事。","lastUpdated":"2020-02-13"},{"id":"中国医药健康产业股份有限公司_史录文","group":"board","name":"史录文","title":"独立董事","isMale":true,"age":"56","degree":"博士","salary":"10.00万","stockAmount":"-","description":"史录文先生,教授,博士研究生导师。曾任国务院城镇居民基本医疗保险试点工作评估专家、卫生部深化医药卫生体制改革专家咨询组专家;历任北京医科大学药学院副院长、后勤部主任、北京大学医学部副主任、北京卫生局局长助理;现任北京大学药学院药事管理与临床药学系教授,博士研究生导师,北京大学医药管理国际研究中心主任;兼任中国药学会药事管理专业委员会副主任委员、中国医院协会药事管理专业委员会常务委员、中国医疗保险研究会常务理事、中国医药创新促进会药物政策专委会副主任委员、中国研究型医院学会儿科专业委员会副主任委员及药物经济学专业委员会主任委员、中国医疗保健国际交流促进会循证药物经济学专委会副主任委员、北京市药学会药物经济学专业委员会主任委员、国家药品监督管理局仿制药质量和疗效一致性评价专家委员会委员;同时,任浙江康恩贝制药股份有限公司董事、弘和仁爱医疗集团有限公司(港股)独立非执行董事。2015年12月至今,任公司独立董事。","lastUpdated":"2020-02-13"},{"id":"中国医药健康产业股份有限公司_强勇","group":"supervisoryCommittee","name":"强勇","title":"监事会主席","isMale":true,"age":"54","degree":"本科","salary":"--","stockAmount":"-","description":"强勇先生,54岁,大学本科,高级会计师。曾任中国通用技术(集团)控股有限责任公司审计部副总经理;三九企业集团审计部部长;中国通用技术(集团)控股有限责任公司审计部总经理。现任中国通用技术(集团)控股有限责任公司专职监事;公司监事、监事会主席。","lastUpdated":"2020-02-13"},{"id":"中国医药健康产业股份有限公司_冯松涛","group":"supervisoryCommittee","name":"冯松涛","title":"监事","isMale":true,"age":"42","degree":"本科","salary":"--","stockAmount":"-","description":"冯松涛先生,42岁,大学本科,高级会计师。曾任中国通用技术(集团)控股有限责任公司财务管理总部预算管理部经理。现任中国通用技术(集团)控股有限责任公司财务管理总部副总经理。","lastUpdated":"2020-02-13"},{"id":"中国医药健康产业股份有限公司_李克洪","group":"supervisoryCommittee","name":"李克洪","title":"监事","isMale":true,"age":"50","degree":"本科","salary":"--","stockAmount":"-","description":"李克洪先生,50岁,大学本科,高级会计师。曾任中国通用技术(集团)控股有限责任公司审计部副总经理。现任中国通用技术(集团)控股有限责任公司审计和风险管控总部副总经理。","lastUpdated":"2020-02-13"},{"id":"中国医药健康产业股份有限公司_刘超","group":"supervisoryCommittee","name":"刘超","title":"职工监事","isMale":true,"age":"48","degree":"本科","salary":"92.90万","stockAmount":"6682","description":"刘超先生,48岁,大学本科。中国医药健康产业股份有限公司总裁办公室主任、高级调研经理兼企业发展部总经理、运营总监。现任中国医药健康产业股份有限公司市场总监、职工监事。","lastUpdated":"2020-01-23"},{"id":"中国医药健康产业股份有限公司_常芙蓉","group":"supervisoryCommittee","name":"常芙蓉","title":"职工监事","isMale":false,"age":"47","degree":"硕士","salary":"62.39万","stockAmount":"-","description":"常芙蓉女士,47岁,硕士,高级会计师、注册会计师。曾任中瑞岳华会计师事务所部门副经理、公司审计监察部副总经理、总经理。现任中国医药健康产业股份有限公司审计部总经理兼纪检室主任、职工监事。","lastUpdated":"2020-01-23"},{"id":"中国医药健康产业股份有限公司_王宏新","group":"manager","name":"王宏新","title":"总经理","isMale":true,"age":"53","degree":"硕士","salary":"82.96万","stockAmount":"-","description":"王宏新先生,53岁,硕士,助理国际商务师。中国医药健康产业股份有限公司综合贸易部总经理、公司总经理助理、董事、副总经理。现任中国医药健康产业股份有限公司总经理。","lastUpdated":"2020-06-18"},{"id":"中国医药健康产业股份有限公司_刘清源","group":"manager","name":"刘清源","title":"董事会秘书","isMale":true,"age":"49","degree":"硕士","salary":"71.27万","stockAmount":"-","description":"刘清源先生,49岁,硕士,高级经济师。曾任陕煤集团化工公司总监、前海金融集团投资公司总经理。现任中国医药健康产业股份有限公司董事会秘书、董事会办公室主任。","lastUpdated":"2020-02-13"},{"id":"中国医药健康产业股份有限公司_刘玮","group":"manager","name":"刘玮","title":"副总经理","isMale":true,"age":"51","degree":"硕士","salary":"88.33万","stockAmount":"-","description":"刘玮先生,51岁,硕士,工程师。曾任通用天方药业集团有限公司总经理、天方药业有限公司总经理。现任中国医药健康产业股份有限公司副总经理。","lastUpdated":"2020-02-13"},{"id":"中国医药健康产业股份有限公司_李欣","group":"manager","name":"李欣","title":"总经理助理","isMale":true,"age":"57","degree":"硕士","salary":"106.3万","stockAmount":"-","description":"李欣先生,57岁,硕士,药剂师。曾任北京美康永正医药有限公司总经理。现任中国医药健康产业股份有限公司总经理助理。","lastUpdated":"2020-02-13"},{"id":"中国医药健康产业股份有限公司_宋健敏","group":"manager","name":"宋健敏","title":"总会计师","isMale":false,"age":"48","degree":"硕士","salary":"88.38万","stockAmount":"-","description":"宋健敏女士,48岁,硕士,注册会计师、英国ACCA会员。曾任中国仪器进出口(集团)公司财务部总经理、中国邮电器材集团公司财务部总经理;公司财务部总经理。现任中国医药健康产业股份有限公司总会计师。","lastUpdated":"2020-02-13"}],"companyName":"中国医药健康产业股份有限公司","province":"北京市","englishName":"China Medicine Health Industry Co Ltd","industry":"医药生物 — 医药商业Ⅱ","website":"www.meheco.com","mainBusiness":"医药领域的生产、加工和贸易","productsName":["原料药","制剂药","中成药","医药商业","国际贸易"],"actualController":"国务院国有资产监督管理委员会","actualControllerSharePercentage":"41.27%","registeredCapital":"10.68亿元","employeeAmount":"8767","phone":"86-010-67164267","location":"北京市东城区光明中街18号","chineseDescription":"中国医药健康产业股份有限公司的主营业务为医药领域的生产、加工和贸易，主要产品有原料药、制剂药、中成药、医药商业、国际贸易。公司在医药行业中继续保持稳定发展趋势。从最新公布的权威行业排名看，2018年度中国医药工业百强榜排名第45位；全国药品流通行业排名位列第9位；2018年度中国医药保健品行业会员企业进口十强；2018年中国中药材及饮片行业会员企业出口十强；2018年中国医疗器械行业会员企业出口十强；2018年度中国医用高分子出口十强企业。公司拥有著名商标“天方”、“德林清”、“德宝康”及驰名商标“京丰”。","foundedDate":"1997-05-08","goPublicDate":"1997-05-15","companyHistory":"中国医药健康产业股份有限公司（以下简称“本公司”)原名中技贸易股份有限公司，成立于1997年5月8日，是经国家体改委“体改生[1997]41号”文件和对外贸易经济合作部“[1997]外经贸政审函字第773号”文件批准，由中国技术进出口总公司（以下简称“中技总公司”）独家发起，以社会募集方式设立的股份有限公司。\n　　经中国证券监督管理委员会证监发字[1997]164号和证监发字[1997]165号文件批准，本公司于1997年4月28日公开发行人民币普通股3,000万股，其中，向社会公开发行2,700万股，向公司内部职工配售300万股，并于同年在上海证券交易所上市交易。发行后本公司注册资本为12,000万元，其中，国有法人股9,000万股，由中技总公司持有；社会公众股3,000万股，在上海证券交易所挂牌交易。\n　　经过历次配股、换股、转增、股权分置改革及送红股等变更,截至2019年12月31日止,本公司股本为人民币1,068,485,534股,其中,无限售条件的流通股为1,068,108,198股,有限售条件的流通股为377,336股。\n　　本公司统一社会信用代码：911100001000265317。本公司注册地址：北京市东城区光明中街18号。法定代表人：高渝文。收起▲","shareholders":[{"organizationId":"03130691","holderName":"中国通用技术(集团)控股有限责任公司","totalShare":"4.41亿","sharePercentage":"41.27%"},{"organizationId":"T000036002","holderName":"通用天方药业集团有限公司","totalShare":"1.08亿","sharePercentage":"10.09%"},{"organizationId":"T000105930","holderName":"上海汽车集团股权投资有限公司","totalShare":"4270.46万","sharePercentage":"4.00%"},{"organizationId":"T000280241","holderName":"中央汇金资产管理有限责任公司","totalShare":"2226.40万","sharePercentage":"2.08%"},{"organizationId":"T000128170","holderName":"通用技术集团医药控股有限公司","totalShare":"1475.10万","sharePercentage":"1.38%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"1143.40万","sharePercentage":"1.07%"},{"organizationId":"","holderName":"中国农业银行股份有限公司-中证500交易型开放式指数证券投资基金","totalShare":"536.52万","sharePercentage":"0.50%"},{"organizationId":"","holderName":"华夏人寿保险股份有限公司-万能保险产品","totalShare":"380.00万","sharePercentage":"0.36%"},{"organizationId":"","holderName":"张志林","totalShare":"357.04万","sharePercentage":"0.33%"},{"organizationId":"","holderName":"林海四","totalShare":"346.00万","sharePercentage":"0.32%"}],"englishDescription":"China Meheco Group Co., Ltd. is mainly engaged in the operation of industrial pharmaceutical, commercial pharmaceutical and international trading businesses. Industrial Pharmaceutical segment mainly involves in the manufacture and distribution of chemical preparations, chemical bulk drugs, biological products, Chinese patent medicine, herbal decoction pieces and other pharmaceutical products. Commercial Pharmaceutical segment is mainly engaged in the wholesale and distribution of pharmaceuticals and medical devices. Trading segment is mainly engaged in the international exporting business and medical resourcing introduction.","englishIndustry":"Medical Equipment & Supplies","Price to earnings (ttm)":"20.78","Price to sales (ttm)":"0.50","Price to book (mrq)":"1.88","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"75.49","Lt debt to equity (mrq)":"16.00","Return on investment (ttm)":"8.85","Return on equity (ttm)":"3.62","Income statement":{},"Balance sheet":{"Cash":"1.03","Cash & equivalents":"2,658.21","Short term investments":"169.27","Cash and short term investments":"2,828.52","Accounts receivable - trade, net":"11,079.26","Total receivables, net":"12,824.52","Total inventory":"6,024.02","Prepaid expenses":"827.69","Other current assets, total":"9.02","Total current assets":"22,513.77","Property/plant/equipment, total - gross":"4,413.38","Accumulated depreciation, total":"(2,060.79)","Property/plant/equipment, total - net":"2,352.59","Goodwill, net":"1,501.35","Intangibles, net":"609.34","Long term investments":"2,441.10","Note receivable - long term":"12.40","Other long term assets, total":"402.10","Total assets":"29,832.66","Accounts payable":"5,909.02","Accrued expenses":"334.11","Notes payable/short term debt":"6,336.18","Current port. of  lt debt/capital leases":"102.00","Other current liabilities, total":"3,158.80","Total current liabilities":"15,840.11","Long term debt":"1,121.70","Capital lease obligations":"0.09","Total long term debt":"1,121.79","Total debt":"7,559.96","Deferred income tax":"7.44","Minority interest":"2,015.71","Other liabilities, total":"1,852.72","Total liabilities":"20,837.76","Common stock, total":"1,068.49","Additional paid-in capital":"2,047.30","Retained earnings (accumulated deficit)":"5,856.29","Other equity, total":"22.82","Total equity":"8,994.90","Total liabilities & shareholders' equity":"29,832.66","Total common shares outstanding":"1,068.49","Tangible book value per share, common eq":"6.44"},"Cash flow":{"Cash receipts":"34,864.85","Cash payments":"(29,656.31)","Cash taxes paid":"(1,125.04)","Changes in working capital":"(4,137.32)","Cash from operating activities":"(53.82)","Capital expenditures":"(280.35)","Other investing cash flow items, total":"(2,825.91)","Cash from investing activities":"(3,106.26)","Financing cash flow items":"(82.10)","Total cash dividends paid":"(553.23)","Issuance (retirement) of debt, net":"2,612.83","Cash from financing activities":"1,977.50","Foreign exchange effects":"5.32","Net change in cash":"(1,177.26)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"16.26","52 Week High":"18.29","52 Week Low":"12.37","Pricing date":"","10 Day Average Trading Volume":"50.35","Market Capitalization":"17,373.57","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"434.45","Beta":"1.17","1 Day Price Change":"2.91","13 Week Price Return (Daily)":"13.47","26 Week Price Return (Daily)":"22.07","5 Day Price Return (Daily)":"5.04","52 Week Price Return (Daily)":"19.91","Year To Date Price Return (Daily)":"24.60","Month to Date Price Return (Daily)":"14.91","Price Relative to S&P500 (4 Week)":"7.48","Price Relative to S&P500 (13 Week)":"-1.96","Price Relative to S&P500 (26 Week)":"9.77","Price Relative to S&P500 (52 Week)":"5.38","Price Relative to S&P500 (YTD)":"14.82"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.92","EPS excl. Extra Items (TTM)":"0.78","EPS Normalized (Annual)":"0.98","Revenue per Share (Annual)":"33.02","Revenue per Share (TTM)":"32.31","Book Value (Per Share Annual)":"8.42","Book Value (Per Share Quarterly)":"8.67","Tangible Book Value (Per Share Annual)":"6.44","Tangible Book Value (Per Share Quarterly)":"6.53","Cash Per Share (Per Share Annual)":"2.65","Cash Per Share (Per Share Quarterly)":"3.04","Cash Flow (Per Share Annual)":"1.38","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.28","Dividends (Per Share TTM)":"0.28","EBITD (Per Share TTM)":"1.55","EPS Basic excl. Extra Items (Annual)":"0.92","EPS Basic excl. Extra Items (TTM)":"0.78","EPS incl. Extra Items (Annual)":"0.92","EPS incl. Extra Items (TTM)":"0.78","Free Cash Flow (Per Share TTM)":"-0.73","Dividend (Per Share 5Y)":"0.30"},"Valuation":{"P/E excl. Extra Items (Annual)":"17.70","P/E excl. Extra Items (TTM)":"20.78","P/E Normalized (Annual)":"16.68","Price to sales (Annual)":"0.49","Price to sales (TTM)":"0.50","Price to Tangible Book (Annual)":"2.52","Price to Tangible Book (Quarterly)":"2.49","Price to Free Cash Flow (Per Share Annual)":"--","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"--","Price to Book (Annual)":"1.93","Price to Book (Quarterly)":"1.88","P/E Basic excl. Extra Items (TTM)":"19.22","P/E excl. Extra Items High (TTM)":"38.49","P/E excl. Extra Items Low (TTM)":"8.63","P/E incl. Extra Items (TTM)":"20.78","Net Debt (Interim)":"3,743.92","Net Debt (Annual)":"4,731.45","Dividend Yield (5Y)":"1.77","Dividend Yield":"1.69","Current Dividend Yield (TTM)":"1.69"},"Financial Strength":{"Free Cash Flow (Annual)":"-887.40","Current Ratio (Annual)":"1.42","Net Interest coverage (Annual)":"11.84","Long Term Debt/Equity (Annual)":"12.47","Payout Ratio (Annual)":"30.00","Quick Ratio (Annual)":"1.04","Total Debt/Total Equity (Annual)":"84.05","Current EV/Free Cash Flow (Annual)":"37.52","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.39","Long Term Debt/Equity (Quarterly)":"16.00","Quick Ratio (Quarterly)":"1.02","Total Debt/Total Equity (Quarterly)":"75.49","Free Cash Flow (TTM)":"-781.22","Net Interest Coverage (TTM)":"7.21","Payout Ratio (TTM)":"35.21"},"Margins":{"Gross Margin (Annual)":"18.08","Gross Margin (TTM)":"17.12","Net Profit Margin % (Annual)":"3.56","Net Profit Margin (TTM)":"3.05","Operating Margin (Annual)":"4.79","Operating Margin (TTM)":"4.13","Pretax Margin (TTM)":"4.13","Pretax Margin (Annual)":"4.80","Operating Margin (5Y)":"5.85","Pretax Margin (5Y)":"5.93","Free Operating Cash Flow/Revenue (5Y)":"-0.19","Free Operating Cash Flow/Revenue (TTM)":"-2.26","Gross Margin (5Y)":"15.92","Net Profit Margin (5Y)":"4.56"},"Management Effectiveness":{"Return on Assets (Annual)":"4.55","Return on Equity (TTM)":"3.62","Return on Average Equity (Annual)":"11.25","Return on Average equity (TTM)":"9.23","Return on Investment (Annual)":"11.00","Return on Investment (TTM)":"8.85","Return on Average Assets (5Y)":"6.23","Return on Average Equity (5Y)":"15.19","Return on Investment (5Y)":"14.11","Asset Turnover (Annual)":"1.28","Asset Turnover (TTM)":"1.19","Inventory Turnover (Annual)":"5.16","Inventory Turnover (TTM)":"4.75","Net Income/Employee (Annual)":"144,458.80","Net Income/Employee (TTM)":"120,043.20","Receivables Turnover (Annual)":"3.44","Receivables Turnover (TTM)":"3.12","Revenue/Employee (Annual)":"4,061,095.00","Revenue/Employee (TTM)":"3,938,080.00"},"Growth":{"Revenue Growth (Quarterly YoY)":"-9.21","Revenue Growth Rate (5Y)":"14.59","EPS Growth (Quarterly YoY)":"-35.49","EPS Growth (TTM YoY)":"-45.26","EPS Growth Rate (5Y)":"11.07","Dividend Growth Rate (3Y)":"1.15","Revenue Growth (TTM YoY)":"5.69","Revenue Growth (Per Share 5Y)":"13.37","Revenue Growth Rate (3Y)":"10.79","EPS Growth Rate (3Y)":"-0.24","Book Value Growth Rate (Per Share 5Y)":"11.37","Tangible Book Value Total Equity CAGR (5Y)":"8.69","Capital Spending growth rate 5 year":"23.67","EBITDA CAGR (5Y)":"16.38","EBITDA Interim CAGR (5Y)":"12.40","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"47.30","Net Profit Margin Growth Rate (5Y)":"0.69"},"Income Statement":{"Revenue (Annual)":"35,284.82","Revenue (TTM)":"34,525.15","EBITD (Annual)":"2,154.84","EBITD (TTM)":"1,654.04","Earnings Before Taxes (Annual)":"1,692.71","Earnings Before Taxes (TTM)":"1,426.87","Net Income to Common (Annual)":"981.35","Net Income to Common (TTM)":"836.08","Earnings Before Taxes Normalized (Annual)":"1,774.22","Net Income Available to Common Normalized (Annual)":"1,041.79","Diluted Normalized EPS excl. Extra Items (TTM)":"0.78"}}}